A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
Status:
Not yet recruiting
Trial end date:
2025-05-06
Target enrollment:
Participant gender:
Summary
The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small
intestinal damage due to gluten exposure, in participants with celiac disease (CeD)
attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo
controls.